COMPANY PROFILE

Icon Bioscience

Icon Bioscience develops and commercializes novel ophthalmic pharmaceuticals through a proprietary drug delivery platform

Sunnyvale, United StatesFounded 2004Biotech & Life Sciences

Valuation $50–100M Last recorded · 2013

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

At a glance

Status: Acquired
Founded: 2004
Headquarters: Sunnyvale, United States
Employees: 2
Open positions: None listed
Dealroom signal: 25.3/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Biotechnology, Ophthalmology, Surgery, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Mar 2018	$0	—	EyePoint Pharmaceuticals	—
CONVERTIBLE✓Equity / VC	Dec 2015	$5.3M	—	Undisclosed	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Icon Bioscience website traffic

Latest recorded traffic for Icon Bioscience is 760 monthly website visits, up 1800% over the last three months. Icon Bioscience's team declined 33.3% over the past year.

Latest monthly visits760 3-month web change+1800% 1-year team growth-33.3%

Monthly website visitsJan 2017–Dec 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
IOIOPtimaDedicated to improving ophthalmic care through the development and commercialization of innovative products addressing a wide range of ocular conditions	Tel Aviv-Yafo, Israel	Acquired	7	$7.2M	$29M
STSling TherapeuticsA clinical-stage biopharmaceutical company developing an oral small molecule for the treatment of thyroid eye disease	Ann Arbor, United States	Operational
OTOcuMension TherapeuticsCompany which focuses on the development of ophthalmic medications	Huangpu, China	Operational
CTCell Care TherapeuticsDeveloping first-in-class stem cell derived biopharmaceuticals to treat inflammatory and degenerative ophthalmic diseases	Long Beach, United States	Operational
TGThe Dermatology GroupA dermatology-focused physician practice management company with 16 company affiliated locations throughout Northern and Central New Jersey	United States	Operational
MMMobile MedicalDiverse company offering both commercial and military/disaster readiness product lines for domestic and international markets	Saint Johnsbury, United States	Operational
OCOcugenA biotech company specializing in vaccines and gene therapies, focusing on public health and unmet medical needs, with a breakthrough modifier gene therapy platform for multiple retinal diseases and ongoing research in COVID-19 vaccine development	Aurora, United States	Operational
PTProQR TherapeuticsDevelops RNA therapies to potentially transform the lives of patients suffering from genetic rare diseases	Leiden, Netherlands	Operational